Insider Selling: Genomic Health, Inc. (NASDAQ:GHDX) Insider Sells 25,000 Shares of Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $71.47, for a total value of $1,786,750.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Steven Shak also recently made the following trade(s):

  • On Tuesday, August 6th, Steven Shak sold 50,000 shares of Genomic Health stock. The shares were sold at an average price of $71.83, for a total value of $3,591,500.00.
  • On Friday, August 2nd, Steven Shak sold 50,000 shares of Genomic Health stock. The shares were sold at an average price of $72.65, for a total value of $3,632,500.00.

Shares of GHDX opened at $70.83 on Friday. Genomic Health, Inc. has a 52 week low of $50.77 and a 52 week high of $92.18. The company has a quick ratio of 5.74, a current ratio of 5.74 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of 67.46 and a beta of 1.00. The stock’s 50-day moving average price is $73.59 and its 200-day moving average price is $64.93.



Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.07. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The company had revenue of $114.14 million for the quarter, compared to the consensus estimate of $110.78 million. During the same quarter in the prior year, the business posted $0.23 earnings per share. Genomic Health’s revenue for the quarter was up 19.4% on a year-over-year basis. As a group, equities analysts anticipate that Genomic Health, Inc. will post 1.51 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of GHDX. Northwestern Mutual Wealth Management Co. boosted its position in shares of Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after buying an additional 493 shares during the period. Manchester Capital Management LLC acquired a new stake in Genomic Health in the first quarter valued at $56,000. Point72 Asset Management L.P. acquired a new stake in Genomic Health in the second quarter valued at $93,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Genomic Health by 29.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after buying an additional 441 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in Genomic Health by 12.7% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock valued at $192,000 after buying an additional 372 shares in the last quarter. 94.00% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on the company. Barclays upgraded Genomic Health from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $45.00 to $72.00 in a report on Tuesday, July 30th. Piper Jaffray Companies downgraded Genomic Health from an “overweight” rating to a “neutral” rating in a report on Monday, July 29th. Deutsche Bank reduced their price target on Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a report on Thursday, May 30th. JPMorgan Chase & Co. raised Genomic Health from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $60.00 to $72.00 in a research report on Monday, July 29th. Finally, BidaskClub cut Genomic Health from a “buy” rating to a “hold” rating in a research report on Tuesday. Eleven research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Genomic Health presently has an average rating of “Hold” and a consensus price target of $69.86.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: How is Preferred Stock Different from Common Stock?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.